19 January 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
Patent Grant
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce that the University of Queensland has informed the Company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec® in India.
The granted patent in India is for a composition of matter patent for the particle itself as well as the manufacturing process relating to how the particle is made and matches the patents granted in the USA, Canada, Europe, Japan, Australia and China.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"The granting of this patent is a further indication of the strength of the intellectual property we have licensed from the University of Queensland and we now have all of the major global territories with granted patents for Nuvec®."
For more information please contact:
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
To hear more, visit |
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44(0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44(0)20 3657 0050 |
| IFC Advisory Ltd Financial PR Graham Herring Zach Cohen | Tel: +44(0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.
N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre?clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.